Atostar Tab.

Atostar Tab.


Negotiable Min Order Quantity Unit

Required Quantity
Place of Origin
Payment Terms
Negotiable
Production method
Negotiable
Shipping / Lead Time
Negotiable / Negotiable
Keyword
atorvastatin calcium anhydrous, circulatory system
Category
Health & Medical
tK Meet
tK Meet

Apply a video call to the Supplier

SEND TO SUPPLIER INQUIRY

DONGWHA PHARM CO LTD

Country / Year Established
South Korea South Korea / 1897
Business type
Manufacturer
Verified Certificate

16

DUNS

Product name Atostar Tab. Certification -
Category Health & Medical Ingredients -
Keyword atorvastatin calcium anhydrous , circulatory system Unit Size -
Brand name - Unit Weigh -
origin Stock -
Supply type - HS code -

Product Information

1. Category

 : Ethical > Circulatory System

 

2. Ingredients

 : 1 tab. contains

atorvastatin calcium anhydrous......10.36 mg

(10 mg as atorvastatin)

atorvastatin calcium anhydrous......41.4 mg

(40 mg as atorvastatin)

 

3. Indications

 1.reduce total-C, LDL-C, apo B, and TG levels and increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia 2.Fredrickson Type IV 3.Fredrickson Type III who do not respond adequately to diet 4.reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia 5.reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls(10-17 years of age) with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient.

The patient should be placed on a standard cholesterol-lowering diet before receiving Atostar and should continue on this diet during treatment with Atostar.

1. Hypercholesterolemia (Heterozygous Familial and Nonfamilial) and Mixed Dyslipidemia (Fredrickson Types IIa and IIb)

The recommended starting dose of Atostar is 10 mg once daily. Patients who require a large reduction in LDL-C (more than 45%) may be started at 20 mg or 40 mg once daily.

The dosage range of Atostar is 10 to 80 mg once daily. Atostar can be administered as a single dose at any time of the day, with or without food.

2. Heterozygous Familial Hypercholesterolemia in Pediatric Patients (10-17 years of age)

The recommended starting dose of Atostar is 10 mg/day; the maximum recommended dose is 20 mg/day (doses greater than 20 mg have not been studied in this patient population).

3. Homozygous Familial Hypercholesterolemia

The dosage of Atostar in patients with homozygous FH is 10 to 80 mg daily. Atostar should be used as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) in these patients or if such treatments are unavailable.

4. Dosage in Patients With Renal Insufficiency

Dosage adjustment in patients with renal dysfunction is not necessary.

5. Efficacy and safety in adults age 70 or older using recommended doses is similar to that seen in the general population.

 

4. Packing Size

 : 30 T, 100 T

 

 5. Related Disease

 : Cardiovascular system

B2B Trade

Price (FOB) Negotiable transportation -
MOQ Negotiable Leadtime Negotiable
Payment Options Negotiable Shipping time Negotiable

DONGWHA PHARM CO LTD

Country / Year Established
South Korea South Korea / 1897
Business type
Manufacturer

16

DUNS

President
KI HWAN PARK
Address
6-8F, 24, NAMDAEMUN-RO, 9-GIL, JUNG-GU, SEOUL, 04522, KOREA, Jung-gu, Seoul, Korea
Product Category
Pharmaceuticals
Year Established
1897
No. of Total Employees
501-1000
Company introduction

In 1897, a small company named ‘Dong WhaYakbang’ was established in Jeong-dong, where Western culture was introduced ata turbulent time in Korean history. A royal court officer of the ChosunDynasty, Byung Ho Min, created Korea’s first Western-style medicine byintegrating the advantages of Western medical techniques into the royal court’ssecret recipe.

This digestive medicine, known as WhalMyung Su, meaning ‘life-saving water’, soothed people’s pain in those turbulenttimes and became a reliable “comrade” for independence fighters. Since itscreation, Whal Myung Su has been loved as the nation’s favorite digestivemedicine for 117 years amid ever-changing social circumstances and greatturmoil due to the company’s conviction that ‘We will save people with goodmedicine’.

We run our company according to the beliefthat making medicine is not a simple business activity, but a sacred andbeautiful duty that brings happiness to humans.

Honorable titles bestowed by the people,such as ‘The First’ or ‘The Best’, are earned through such a conviction.

Now, Dong Wha Pharm, as Korea’s first andoldest pharmaceutical company, is ready to launch a new era of 100 years basedon such pride. We will abide by our founder’s first intent, ‘Do not make anymedicines but good medicines’. We will be reborn as a self-regulating, adaptivecompany through change and innovation. Based on our accumulated technology and experience,we will make new products of the highest quality. With our happiness managementphilosophy, we will make Dong Wha as the company where each employee can havebig dreams.

Lastly, we will contribute to human healthand happiness. Please join us in exploring this new era.

* Dong Wha Pharm Research Institute, the Backbone of New MedicineDevelopment

Since its establishment in 1973, Dong WhaPharm Research Institute has developed numerous superior medicines and the mostadvanced drugs. It is now set to become a global hub for new drug development.

In order to create a new world-class drug,the research center will focus on R&D (Research and Development), andexpand its assistance and investment on fostering professional human resources.

*  World-class advanced production facilities, Chungju cGMP plant

In 2009, at the Chungju Industrial Complex,Dong Wha Pharm completed the construction of state-of-the-art production facilities,comprising of four stories aboveground and one underground level with a totalof 82,500m2 including total floor space of 52,644m2.

The Chungju Plant is equipped withequipment and facilities that satisfy Current Good Manufacturing Practice(cGMP) Regulations of US F. D. A. In addition, the plant has been evaluated asa world-class pharmaceutical company by the installment of high-tech plantautomation system.

Dong Wha Pharm pursues 100% zero defectswith its independent quality assurance system, which encompasses the procurementof raw materials, production processes, packaging and shipment.

Main Markets

Germany Germany

Indonesia Indonesia

Japan Japan

Mexico Mexico

Portugal Portugal

Spain Spain

U.S.A U.S.A

Viet Nam Viet Nam

Factory Information

DONG WHA CHUNGJU PLANT

Main Product

Related Products

Other buyers also search

Membership Grade

BUYER

Biz Pro VIP

SELLER

Biz Pro VIP
팝업닫기
Live Chat A new message arrives
from a business partner.

No Data

  • There is no data to load
  • Check out the My tK > My Inquiries list.
  • After agreeing to the use of the Live Chat service, the list is printed only when there is at least one history of receiving or sending a Live Chat request.

If you have not yet agreed to use the Live Chat service,

You can use the Live Chat freely after agreeing to the use of the Live Chat service.

View more
View more